SAN DIEGO, Jan. 5, 2018 — Abide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes, announced today that Alan Ezekowitz, CEO and President, will present an overview of the company at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11th at 9:30 a.m. PT in San Francisco.
About Abide Therapeutics
Abide Therapeutics is focused on developing first-in-class drugs for serious diseases with significant unmet medical need. An innovative discovery platform and a library of proprietary small molecules allow Abide to address biological pathways with therapeutics that enhance the body's normal physiological response to disease. The platform enables Abide to efficiently identify, modify, and validate small-molecule inhibitors that target serine hydrolases, a highly relevant but under-explored class of enzymes. Abide's initial area of focus is on addressing neurological disorders with limited treatment options through the endocannabinoid pathway.
Abide has offices in San Diego, California and Princeton, New Jersey. To learn more, visit www.abidetx.com.
Media Contact:
Patty Pilon
Abide Therapeutics
Tel: +1 619.244.2679
[email protected]x.com
Investor Contact:
John Graziano
The Trout Group
Tel: +1 646.378.2942
[email protected]
View original content with multimedia:http://www.prnewswire.com/news-releases/abide-therapeutics-to-present-at-the-36th-annual-jp-morgan-healthcare-conference-300578050.html
SOURCE Abide Therapeutics
Related Links
Powered by WPeMatico
